| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.94M | 4.59M | 3.63M | 5.56M | 4.10M |
| Gross Profit | 1.47M | 1.38M | 1.57M | 2.52M | -1.01M |
| EBITDA | -3.69M | -4.95M | -7.05M | -6.55M | -6.36M |
| Net Income | -3.93M | -5.99M | -5.56M | -4.94M | -3.53M |
Balance Sheet | |||||
| Total Assets | 11.05M | 10.37M | 13.06M | 12.16M | 11.40M |
| Cash, Cash Equivalents and Short-Term Investments | 3.96M | 1.92M | 2.64M | 1.61M | 182.60K |
| Total Debt | 1.74M | 2.78M | 3.26M | 2.41M | 3.98M |
| Total Liabilities | 4.36M | 5.76M | 6.53M | 5.32M | 6.44M |
| Stockholders Equity | 6.70M | 4.61M | 6.53M | 6.84M | 4.96M |
Cash Flow | |||||
| Free Cash Flow | -2.54M | -4.06M | -4.45M | -2.76M | -4.56M |
| Operating Cash Flow | -2.35M | -4.04M | -4.33M | -2.57M | -2.85M |
| Investing Cash Flow | -190.60K | -20.38K | -118.17K | -26.90K | -1.71M |
| Financing Cash Flow | 4.80M | 3.37M | 5.51M | 4.08M | 1.81M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | £574.80M | 22.03 | 8.49% | 2.09% | 0.49% | 61.73% | |
73 Outperform | £79.27M | 19.70 | 7.39% | ― | 36.61% | ― | |
70 Neutral | £78.43M | 17.81 | 9.34% | ― | 7.36% | 31.93% | |
68 Neutral | £97.73M | 41.08 | 3.88% | 1.56% | 8.75% | -54.73% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
54 Neutral | £195.87M | -2.81 | -31.42% | ― | -16.33% | -448.12% | |
40 Underperform | £13.33M | -4.60 | -69.49% | ― | 3.38% | 82.76% |
CAP-XX Limited has received approval from the Australian Tax Office for an R&D tax credit of A$1.75m, and the funds have been paid to the company, bringing its current cash position to A$2.97m. The tax credit injection strengthens CAP-XX’s near-term liquidity as it continues to develop and commercialise its supercapacitor technology, providing additional financial headroom that may support ongoing R&D activities and underpin operations in a competitive energy storage and power management market.
The most recent analyst rating on (GB:CPX) stock is a Sell with a £0.23 price target. To see the full list of analyst forecasts on CAP-XX Ltd stock, see the GB:CPX Stock Forecast page.
CAP-XX Limited has announced that its total issued ordinary share capital consists of 5,797,326,778 ordinary shares, each with one voting right. This information is crucial for shareholders to determine their interest or changes in interest in the company’s share capital, impacting how they engage with CAP-XX’s financial operations.
The most recent analyst rating on (GB:CPX) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on CAP-XX Ltd stock, see the GB:CPX Stock Forecast page.
CAP-XX Ltd has issued 7,303,025 ordinary shares to its Chairman, Dr. Graham Cooley, in lieu of certain fees, as part of its strategy to conserve cash resources. This issuance, priced at 0.275 pence per share, increases Dr. Cooley’s shareholding to 10.53% of the company’s enlarged share capital. The new shares are expected to be admitted to trading on AIM around 20 November 2025, which will adjust the company’s total issued share capital to 5,797,326,778 ordinary shares.
The most recent analyst rating on (GB:CPX) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on CAP-XX Ltd stock, see the GB:CPX Stock Forecast page.
CAP-XX Limited announced that Dr. Graham Cooley, the Non-Executive Chairman, has purchased 24,000,000 ordinary shares, increasing his stake to approximately 10.41% of the company’s issued share capital. This move signifies confidence in the company’s future prospects and may influence investor sentiment positively, potentially impacting CAP-XX’s market position and stakeholder interests.
The most recent analyst rating on (GB:CPX) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on CAP-XX Ltd stock, see the GB:CPX Stock Forecast page.
CAP-XX Limited reported a 7.6% increase in total revenue for the fiscal year ending June 2025, with significant improvements in operational efficiency and strategic partnerships. The company saw a 40.5% improvement in EBITDA loss and a 36.0% reduction in loss after tax, reflecting strong commercial expansion and operational advancements. Key distribution agreements and improved production capabilities have set a robust foundation for FY26, with early trading showing a positive trajectory. The company is well-positioned to capitalize on the growing global demand for supercapacitors, supported by enhanced distribution channels and a strong cash position.
The most recent analyst rating on (GB:CPX) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on CAP-XX Ltd stock, see the GB:CPX Stock Forecast page.